GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » NeuBase Therapeutics Inc (STU:O7P) » Definitions » Research & Development

NeuBase Therapeutics (STU:O7P) Research & Development : €3.98 Mil (TTM As of Sep. 2023)


View and export this data going back to 2019. Start your Free Trial

What is NeuBase Therapeutics Research & Development?

Research & Development is the aggregate amount of research and development expenses during the year. NeuBase Therapeutics's Research & Development for the three months ended in Sep. 2023 was €0.36 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Sep. 2023 was €3.98 Mil.


NeuBase Therapeutics Research & Development Historical Data

The historical data trend for NeuBase Therapeutics's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NeuBase Therapeutics Research & Development Chart

NeuBase Therapeutics Annual Data
Trend Sep12 Sep13 Sep14 Sep15 Sep16 Sep17 Sep18 Sep19 Sep20 Sep21
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 14.60 3.70 14.91 5.90 12.21

NeuBase Therapeutics Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5.54 1.28 1.16 1.19 0.36

NeuBase Therapeutics Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was €3.98 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


NeuBase Therapeutics  (STU:O7P) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.


NeuBase Therapeutics Research & Development Related Terms

Thank you for viewing the detailed overview of NeuBase Therapeutics's Research & Development provided by GuruFocus.com. Please click on the following links to see related term pages.


NeuBase Therapeutics (STU:O7P) Business Description

Traded in Other Exchanges
Address
350 Technology Drive, Suite 421, Pittsburgh, PA, USA, 15219
NeuBase Therapeutics Inc is a pre-clinical stage biopharmaceutical company. It is engaged in the development of gene silencing therapies with its synthetic antisense oligonucleotides. Its Patrol platform is focused on the development of drugs for rare genetic diseases such as Huntington's Disease, Myotonic Dystrophy and Familial Parkinson's Disease among others.

NeuBase Therapeutics (STU:O7P) Headlines

No Headlines